Multidrug resistance in brain tumors: roles of the blood-brain barrier

Area of Science:

• Neuro-oncology
• Cancer Biology
• Pharmacology

Background:

• Malignant brain tumors and metastases are difficult to treat, with limited therapeutic advances.
• Multidrug resistance (MDR) is a primary cause of chemotherapy failure in central nervous system (CNS) cancers.
• The MDR1 gene, encoding P-glycoprotein (P-gp), is crucial for MDR and highly expressed at the blood-brain barrier (BBB).

Purpose of the Study:

• To review evidence linking P-gp expression in primary brain tumors to chemotherapy resistance.
• To elucidate the role of the BBB and P-gp in CNS tumor treatment failure.

Main Methods:

• Literature review of studies on P-gp expression in brain tumors.
• Analysis of P-gp's function as a drug efflux pump at the BBB.
• Examination of the clinical implications of P-gp in brain tumor chemotherapy.

Main Results:

• P-glycoprotein (P-gp) is a key determinant of MDR in various cancers.
• High P-gp expression is observed in the blood-brain barrier (BBB).
• Evidence suggests P-gp is present in primary brain tumors, contributing to treatment resistance.

Conclusions:

• P-glycoprotein (P-gp) is a critical factor in the clinical resistance of brain tumors to chemotherapy.
• Understanding P-gp's role at the BBB is vital for developing effective CNS cancer treatments.
• Targeting P-gp may overcome MDR and improve chemotherapy outcomes for brain tumor patients.